Clinical Dosage Form Development or an Early Approach to Achieve Peak Sales

Courtesy of Somma Tech Consulting Company

Clinical Dosage Form Development or an Early Approach to Achieve Peak Sales Step #1

Pharmaceutical Development continues to present many fundamental challenges when dealing with promising drug lead opportunities. This is a factor across all therapeutic areas from Central Nervous System (CNS) to oncology. In an effort to design new molecular entities which are increasingly effective while minimizing unwanted side effects we at times create drug compounds which are poorly soluble or are unstable and difficult to handle during manufacture. While these issues are primarily physicochemical in nature we further complicate the situation by not applying proven techniques during the early phase development of the clinical dosage form to be used in our development program. The thinking here being that we need to minimize early investment while conducting these early studies with the expectation to correct these interim clinical dosage form shortcomings as we approach late phase and commercialization.  This is a flawed approach and ultimately leads to product and process failures during subsequent late phase efforts. How a firm manages the initial steps during development and compound identification may maximize commercial success or set a course for a series of missed opportunities. Success is not necessarily the first to market but rather the first product to achieve peak sales and market dominance. In this series of blogs we plan to touch upon several aspects which will aid formulators, process engineers and project leaders to consider during early phase development leading to late phase and commercialization.

Clinical Dosage Form Development or an Early Approach to Achieve Peak Sales Step #2

We have begun our discussion around the early phase of compound identification and subsequent selection of a clinical dosage form.  This step of compound selection has many variants so we should consider this dimension for a moment. In a fully integrated firm the compounds are transferred to product development from the discovery group through chemical development. The other conduit is through compound purchase from partners or in some cases a firm which specializes in molecular development such as an NCE “boutique”. In any case the chemical development scientists are faced with their own challenges none the least of which is crafting a process which produces a compound with minimal by products as well as one which is economical to synthesize. During the chemical process development phase a key decision point is reached. That aspect involves the salt selection as well as the base stable form of the compound to avoid potential problems due to polymorphic shifts in the drug substance. A balance of stability as well as by products requires careful consideration as to the salt form selected. The choice of the most economical or easier synthesis is not all ways the best selection and may result in problems during clinical dosage form development. It is not unusual to be asked to formulate a dosage form when presented with a “tar like” drug substance. While there are options one may pursue here the downside is a less the optimal dosage form and delays in bringing the drug candidate into a commercially viable posture.

Given this potential genesis for our drug candidate the formulator must be a part of the compound selection process and minimally the salt selection. All too often we are not part of this decision process and are faced with a difficult task. Having been faced with this several times I can say that we do have alternatives. If the intent is simply to prove effectiveness in humans we can take the time proven route of powder in a bottle or more commonly known as PIB. In its essence this is the most basic clinical dosage form wherein we simply load the drug substance into appropriately selected containers and supply separately a suspending agent and diluent. The clinical study center personnel suspend the drug at the time of administration to the volunteers / patients. Unfortunately we have a less than optimal dosage form but it is here that the formulator has a chance to learn about the drug substance. This enlightenment takes the form of getting insight into the physicochemical properties, micromeritics of the material since after all it needs to be somewhat flowable, stability, as well as the surface activity in suspension. Never miss an opportunity to gain dosage form manufacturing knowledge as this will pay benefits during later phases. We will continue to discuss clinical dosage form evolution from this aspect.


Learn more about the single source for complete biopharmaceutical manufacturing solutions that gathers 12,000 industry professionals each year.


Official blog of: INTERPHEX New York -
This entry was posted in Uncategorized and tagged , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s